PainReform Ltd.

General Information


We are a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary extended release drug-delivery system prolongs the in vivo activity of APIs (active pharmaceutical ingredients), thus increasing the therapeutic window for patient treatment. Our strategy is to incorporate generic drugs with our proprietary extended release drug-delivery system in order to create extended release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (“FDA”). 

Employees: 3
Founded: 2007
Contact Information
Address 60C Medinat Hayehudim, Herzliya, 4676670, Israel
Phone Number +972 9-960-1901
Web Address
View Prospectus: PainReform Ltd.
Financial Information
Market Cap $78.8mil
Revenues $0 mil (last 12 months)
Net Income $-1.3 mil (last 12 months)
IPO Profile
Symbol PRFX
Exchange NASDAQ
Shares (millions): 2.6
Price range $8.00 - $10.00
Est. $ Volume $23.0 mil
Manager / Joint Managers Maxim Group/ Joseph Gunnar
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change